Lupin shares continue to rise, trading at a new 52-week high of Rs 2,376 after a 15% return over two weeks. The Nifty Pharma index's December outperformance highlights buying interest in pharma stocks amid market uncertainty. Analysts recommend buying on dips towards Rs 2,300 with targets around Rs 2,500 as bullish patterns and strong market share bolster Lupin's investment appeal.
